LOBE Lobe Sciences Ltd.

0.0350USD0.0500 CAD · CNQ0.00%Mkt Cap: 10.77M USDP/E: —

Lobe Sciences Ltd., a biopharmaceutical company, engages in the research and development of lipid technology to develop innovative treatments for orphan and rare diseases. It offers Altemia® MF, a medical food designed t…

Key Statistics

Company
Market Cap10.77M USD
Enterprise Value8.29M USD
Revenue (TTM)—
Gross Profit0 USD
Net Income (TTM)-3.10M USD
Revenue/Share—
Last Price0.0350 USD
Fiscal Year EndAug 2025
MR QuarterMay 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISINCA53946V2066
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B7.14
EPS (TTM)-0.03 USD
EPS (Forward)—
52W Range
0.021013% of range0.1258
52W High0.1258 USD
52W Low0.0210 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-187.94%
ROA-58.34%
ROIC—
ROCE-80.88%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-990.63K USD
CapEx (TTM)—
FCF Margin—
FCF Yield-25.24%
Net Debt-3.40M USD
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity0.12
Current Ratio2.38
Quick Ratio2.24
Book Value/Sh0.0049 USD
Cash/Share0.01 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateJun 10, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.308.18M
Float126.94M
Insiders54.18%
Institutions0.00%
Short Interest
Short Ratio0.0d
Short % Out.0.00%
Shares Short387
Short (prev mo.)507
Technical
SMA 500.0384 (-8.9%)
SMA 2000.0555 (-37.0%)
Beta0.16
S&P 52W Chg12.00%
Avg Vol (30d)149.24K
Avg Vol (10d)51.64K
Technical Indicators
RSI (14)51.4
MACD-0.0025
MACD Signal-0.0049
MACD Hist.+0.0024
BB Upper0.0389 USD
BB Middle0.0304 USD
BB Lower0.0219 USD
BB Width56.01%
ATR (14)0.0043 USD
Vol Ratio (20d)0.59x

About Lobe Sciences (CNSX: LOBE)

›

Lobe Sciences (CNSX: LOBE) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.

The shares were at 0.0500 CAD on 19 November 2026, up 11.1% over 52 weeks. Its 52-week range is 0.0300 CAD to 0.1800 CAD: the price is 72.2% below the high and 66.7% above the low.

Its market capitalisation is 15.41M CAD.

Lobe Sciences reports return on equity of -187.9% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 4.87M CAD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.